

Nippon Shinyaku:Leading Products

Performance (consolidated)

(¥ million)

	2018 (JGAAP)	2019 (JGAAP)	2020 (IFRS)	2021 (IFRS)	2022 (IFRS)	2023 (IFRS)	2024 (IFRS) (estimated)
Revenue	114,716	116,637	121,859	137,484	144,175	148,255	154,000
Operating profit	20,644	21,668	27,202	32,948	30,049	33,295	32,000
Profit before tax	21,540	22,442	27,608	33,301	30,489	33,616	32,500
Profit attributable to owners of parent	16,302	16,866	19,540	24,986	22,812	25,851	29,000

August 7, 2024

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2022 (IFRS)	Sales 2023 (IFRS)	Sales 2024 (IFRS)		
						Apr-Jun	Apr-Sep (estimated)	Annual (estimated)
Viltepso	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	14,341	17,530	5,450	10,300	20,600
(Japan)				(4,139)	(4,407)	1,175	2,300	4,600
(U.S.)				(10,201)	(13,123)	4,275	8,000	16,000
Upravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	10,543	12,918	3,855	7,600	15,400
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	15,951	10,383	1,462	2,600	4,800
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,904	4,695	1,254	2,500	5,100
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	5,358	3,927	778	1,400	2,700
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,524	2,221	709	1,100	2,300
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,938	2,499	647	1,400	2,700
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	2,826	2,256	493	850	1,600
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	2,649	2,255	480	900	1,700
Erizas	dexamethasone cipeclilate	allergic rhinitis	Dec-2009	2,640	2,284	281	700	2,100
Profit in co-promotion				9,520	8,658	2,461	4,550	9,100
Revenues from the licensing of industrial property rights				30,714	40,304	10,779	21,000	42,100
Pharmaceuticals				121,988	125,105	33,738	65,300	132,500
Functional Food				22,187	23,150	5,393	10,500	21,500
Revenue				144,175	148,255	39,131	75,800	154,000